Get the Stockscreener App
0.7267
3.11%
-0.0233
Ironwood Pharmaceuticals Inc stock is traded at $0.7267, with a volume of 3.33M.
It is down -3.11% in the last 24 hours and down -52.81% over the past month.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
See More
Previous Close:
$0.75
Open:
$0.7492
24h Volume:
3.33M
Relative Volume:
0.91
Market Cap:
$104.84M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
18.17
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
-28.05%
1M Performance:
-52.81%
6M Performance:
-83.63%
1Y Performance:
-90.50%
1-Day Range:
$0.7002
$0.7801
1-Week Range:
$0.591
$1.02
52-Week Range:
$0.591
$8.45
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
0.7267 | 104.84M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN
Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN
Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN
Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus
Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN
Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Ironwood stock downgraded at Jefferies (IRWD:NASDAQ) - Seeking Alpha
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 - marketscreener.com
Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 - MarketScreener
Ironwood crashes down as FDA seeks new phase 3 trial - Pharmaphorum
Ironwood (IRWD) Shares Downgraded by Jefferies Following FDA Set - GuruFocus
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock News - GuruFocus
Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | I - GuruFocus
Ironwood To Consider All Options With Apraglutide Setback In SBS - insights.citeline.com
Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize
Ironwood requires new trial for SBS drug approval By Investing.com - Investing.com South Africa
Top Midday Decliners - MarketScreener
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga
Ironwood to considers merger opportunities after FDA setback - The Business Journals
Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Benzinga
Ironwood (IRWD) Faces Financial Uncertainty as Price Target is S - GuruFocus
Ironwood (IRWD) Faces Financial Uncertainty as Price Target is Slashed | IRWD Stock News - GuruFocus
Ironwood: FDA nay on PK means another apraglutide study - BioWorld MedTech
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - BioSpace
Ironwood Pharmaceuticals (IRWD) Considers Strategic Options Afte - GuruFocus
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial By Investing.com - Investing.com India
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial - Investing.com Australia
Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Benzinga
Ironwood Says FDA to Require Additional Phase 3 Trial for Apraglutide; to Explore Strategic Options - MarketScreener
Ironwood Pharma stock down on regulatory hurdle (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharma Provides Update On Apraglutide; Plans Strategic Alternatives - Nasdaq
Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Followin - GuruFocus
Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Following FDA Talks | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com
Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth - Seeking Alpha
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Stock Sentiment: What’s Wall Street Saying? - stocksregister.com
Short Bowel Syndrome Market Growth Projections 2024-2034: - openPR.com
IRONWOOD PHARMACEUTICALS INC SEC 10-K Report - TradingView
Ironwood Pharmaceuticals (IRWD) Faces Nasdaq Compliance Deadline - GuruFocus
Ironwood Pharmaceuticals Gets Nasdaq Non-Compliance Notice - MarketScreener
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing - Business Wire
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Charles Schwab Investment Management Inc. Has $8.79 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Irritable Bowel Syndrome Treatment Market Future Business - openPR.com
StockNews.com Downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to Hold - Armenian Reporter
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD): Blank Check On Growth? - Stocks Register
Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $8.60 - Defense World
Ironwood Announces Rolling Apraglutide NDA Submission for Short Bowel Syndrome - AJMC
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ironwood Pharmaceuticals Inc Stock (IRWD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silver Ronald | Principal Accounting Officer |
Feb 10 '25 |
Sale |
1.76 |
12,048 |
21,204 |
279,655 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 10 '25 |
Sale |
1.76 |
41,269 |
72,633 |
554,007 |
| John Minardo | Chief Legal Officer |
Feb 10 '25 |
Sale |
1.76 |
38,938 |
68,531 |
408,132 |
| Martini Gregory S. | Chief Financial Officer |
Feb 10 '25 |
Sale |
1.76 |
12,052 |
21,212 |
183,810 |
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):